William R. Hiatt

Q: What Schools Are Affiliated With William R. Hiatt

William R. Hiatt is affiliated with the following schools: University of Minnesota, University of Colorado Denver, University of California, Los Angeles, University of Colorado, Case Western Reserve University, University of Washington, University of California, San Francisco, New York University, Duke University

William R. Hiatt's AcademicInfluence.com Rankings

William R. Hiatt

Philosophy

#4140

World Rank

#6542

Historical Rank

#1241

USA Rank

Logic

#1670

World Rank

#2480

Historical Rank

#477

USA Rank

philosophy Degrees

Download Badge

Philosophy

William R. Hiatt's Degrees

Doctorate Medicine University of California, San Francisco
PhD Physiology University of California, San Francisco

Why Is William R. Hiatt Influential?

(Suggest an Edit or Addition)

According to Wikipedia, William R. Hiatt was an American cardiologist. William H. Hiatt was born in Albion, Indiana, on 19 December 1919, educated at Manchester College and the Loyola University School of Dentistry, and moved to Colorado to pursue a career in endodontics and periodontics. He died of cancer on 31 May 1993. Hiatt married Luana Read, with whom he had three children, including William R. Hiatt, who was born on 1 June 1950. William R. Hiatt graduated from Denver Country Day School in 1968, and studied English at Knox College, where he first met his wife Susan Wessels Hiatt. After completing his undergraduate degree in 1972, Hiatt enrolled at the University of Colorado School of Medicine until 1976. He successively held a residency at Boston University Hospital in internal medicine, followed by a fellowship in vascular medicine at the University of Colorado. Hiatt began teaching at the University of Colorado in 1981, and was later named Novartis Foundation Endowed Chair in Cardiovascular Research. Hiatt was associated with the EUCLID and VOYAGER clinical trials up to his death on 8 December 2020.

(See a Problem?)

William R. Hiatt's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). (2007) (5259)
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). (2007) (2725)
Inter-society consensus for the management of peripheral arterial disease. (2007) (2213)
Peripheral arterial disease detection, awareness, and treatment in primary care. (2001) (1613)
Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care (2001) (1164)
Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. (2012) (1135)
Medical treatment of peripheral arterial disease and claudication. (2001) (1119)
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. (1998) (877)
Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations (2016) (654)
Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. (1995) (561)
Exercise training for claudication. (2002) (536)
Benefit of exercise conditioning for patients with peripheral arterial disease. (1990) (490)
Peripheral arterial disease in patients with diabetes. (2006) (478)
Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease (2003) (474)
Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery Disease (2017) (411)
Exercise training improves functional status in patients with peripheral arterial disease. (1996) (402)
A comparison of cilostazol and pentoxifylline for treating intermittent claudication. (2000) (398)
Rivaroxaban in Peripheral Artery Disease after Revascularization. (2020) (365)
Reduction of polygalacturonase activity in tomato fruit by antisense RNA. (1988) (361)
Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. (1994) (356)
Expression in plants of a mutant aroA gene from Salmonella typhimurium confers tolerance to glyphosate (1985) (354)
Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. (2014) (328)
Enhanced levels of the aroma and flavor compound S-linalool by metabolic engineering of the terpenoid pathway in tomato fruits. (2001) (295)
The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program (2008) (293)
Functional outcome in a contemporary series of major lower extremity amputations. (2003) (292)
Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. (1995) (286)
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. (2010) (280)
Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. (2004) (275)
Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia (2011) (273)
Chronic Changes in Skeletal Muscle Histology and Function in Peripheral Arterial Disease (1993) (261)
A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. (2012) (260)
Dietary Sodium Restriction Rapidly Improves Large Elastic Artery Compliance in Older Adults With Systolic Hypertension (2004) (252)
Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes (2003) (249)
Effect of Cilostazol on Treadmill Walking, Community‐Based Walking Ability, and Health‐Related Quality of Life in Patients with Intermittent Claudication Due to Peripheral Arterial Disease: Meta‐Analysis of Six Randomized Controlled Trials (2002) (247)
Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus. (1998) (246)
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study (2018) (244)
Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). (2015) (243)
Hospital vs Home-Based Exercise Rehabilitation for Patients with Peripheral Arterial Occlusive Disease (1997) (231)
Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. (1996) (226)
Inflammation in Peripheral Artery Disease (2010) (221)
Effects of non-insulin-dependent diabetes on oxygen consumption during treadmill exercise. (1995) (219)
Diagnostic methods for peripheral arterial disease in the San Luis Valley Diabetes Study. (1990) (212)
An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) (2015) (211)
BISTABLE SWITCHING IN NIOBIUM OXIDE DIODES (1965) (206)
A single amino acid substitution in the enzyme 5-enolpyruvylshikimate-3-phosphate synthase confers resistance to the herbicide glyphosate. (1985) (206)
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (2018) (190)
Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness. (2001) (176)
The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. (2013) (171)
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. (2009) (169)
Postharvest evaluation of transgenic tomatoes with reduced levels of polygalacturonase: processing, firmness and disease resistance (1992) (169)
Cardiovascular drug development: is it dead or just hibernating? (2015) (159)
An update on methods for revascularization and expansion of the TASC lesion classification to include below‐the‐knee arteries: A supplement to the inter‐society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee* (2015) (157)
An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries (2015) (155)
The Evaluation of Exercise Performance in Patients with Peripheral Vascular Disease (1988) (154)
A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life. (2008) (154)
Utility and barriers to performance of the ankle brachial index in primary care practice (2004) (148)
Current medical therapies for patients with peripheral arterial disease: a critical review. (2002) (147)
Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. (2011) (144)
Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options. (2016) (143)
Carnitine and acylcarnitine metabolism during exercise in humans. Dependence on skeletal muscle metabolic state. (1989) (143)
Effects of exercise training on oxygen uptake kinetic responses in women with type 2 diabetes. (1999) (142)
Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease (2000) (139)
Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. (1992) (137)
Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. (2008) (136)
Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association (2019) (134)
Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. (2015) (132)
Effect of Hypoxia-Inducible Factor-1&agr; Gene Therapy on Walking Performance in Patients With Intermittent Claudication (2011) (131)
Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial (2007) (129)
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). (2008) (122)
Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. (2006) (121)
Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease. (2015) (117)
Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease. (1999) (115)
A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. (2017) (114)
Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease (1999) (113)
Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. (2011) (106)
An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Comittee(.). (2015) (103)
Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. (2001) (102)
The use of velocity wave form analysis in the diagnosis of carotid artery occlusive disease. (1977) (101)
Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandins. (1983) (101)
Is revascularization and limb salvage always the best treatment for critical limb ischemia? (2003) (101)
Impaired muscle oxygen use at onset of exercise in peripheral arterial disease. (2004) (99)
Wound healing and functional outcomes after infrainguinal bypass with reversed saphenous vein for critical limb ischemia. (2006) (99)
Angiogenesis in Skeletal Muscle Precede Improvements in Peak Oxygen Uptake in Peripheral Artery Disease Patients (2011) (98)
A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication (2010) (98)
Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication (2001) (95)
Structure and expression of elongation factor 1α in tomato (1989) (94)
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD) (2018) (93)
Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. (1999) (93)
Intermediate-term outcome of primary digit amputations in patients with diabetes mellitus who have forefoot sepsis requiring hospitalization and presumed adequate circulatory status. (1999) (92)
Carnitine metabolism during exercise in patients with peripheral vascular disease. (1987) (92)
Assessment of functional status and quality of life in claudication. (2011) (91)
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease (2017) (90)
Isolation, sequence, and expression in Escherichia coli of the Pseudomonas sp. strain ACP gene encoding 1-aminocyclopropane-1-carboxylate deaminase (1991) (88)
Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. (2003) (87)
Clinical and demographic predictors of exercise capacity in end-stage renal disease. (2002) (87)
Cardiovascular disease mortality in Hispanics and non-Hispanic whites. (2002) (86)
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial (2015) (85)
Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. (2013) (85)
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program (2019) (83)
Effect of intravenous L‐carnitine on carnitine homeostasis and fuel metabolism during exercise in humans (1994) (83)
Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial design. (2008) (82)
Medical Therapy in Peripheral Artery Disease (2012) (76)
Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. (2001) (76)
Evaluating effects of method of administration on Walking Impairment Questionnaire. (2003) (74)
Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussion (2004) (74)
Fruit‐specific expression of the A. tumefaciens isopentenyl transferase gene in tomato: effects on fruit ripening and defense‐related gene expression in leaves (1994) (73)
Muscle denervation in peripheral arterial disease (1992) (73)
Globoid cell leukodystrophy: deficiency of lactosyl ceramide beta-galactosidase. (1974) (70)
Fibrates in the treatment of dyslipidemias--time for a reassessment. (2011) (69)
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE (2016) (66)
Pharmacologic therapy for peripheral arterial disease and claudication. (2002) (65)
Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. (1985) (65)
Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease (2007) (64)
Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol (1999) (64)
Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization. (2018) (64)
The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. (1998) (64)
Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group. (1999) (63)
Venous occlusion plethysmography reduces arterial diameter and flow velocity. (1989) (63)
Functional Benefits of Peripheral Vascular Bypass Surgery for Patients with Intermittent Claudication (1993) (62)
Exercise Testing and Exercise Rehabilitation for Patients with Peripheral Arterial Disease: Status in 1997 (1997) (62)
The Treadmill Is a Better Functional Test Than the 6-Minute Walk Test in Therapeutic Trials of Patients With Peripheral Artery Disease (2014) (62)
Electrode effects and bistable switching of amorphous Nb2O5 diodes (1970) (61)
Developmental analysis of elongation factor-1 alpha expression in transgenic tobacco. (1991) (61)
Carnitine metabolism during exercise in patients on chronic hemodialysis. (1992) (60)
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. (2013) (59)
Functional Benefits of Peripheral Vascular Bypass Surgery for Patients with Intermittent Claudication (1993) (59)
Gait characteristics of patients with claudication. (1998) (58)
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess? (2016) (56)
Carnitine and Peripheral Arterial Disease (2004) (56)
Progression of neuropathy in peripheral arterial disease (1995) (55)
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings (2015) (54)
Skeletal muscle StO2 kinetics are slowed during low work rate calf exercise in peripheral arterial disease (2007) (52)
PAD awareness, risk, and treatment: new resources for survival - the USA PARTNERS program (2001) (51)
Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training (2012) (51)
Methylation of elongation factor 1 alpha from the fungus Mucor. (1982) (51)
Carnitine metabolism during exercise. (1994) (50)
Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication (2001) (49)
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. (2016) (49)
The next 10 years in the management of peripheral artery disease: perspectives from the 'PAD 2009' Conference. (2010) (49)
Observational studies of drug safety--aprotinin and the absence of transparency. (2006) (48)
Quantification of carnitine, acetylcarnitine, and total carnitine in tissues by high-performance liquid chromatography: the effect of exercise on carnitine homeostasis in man. (1995) (48)
Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. (2018) (47)
Peripheral arterial disease rehabilitation: a review. (2003) (47)
Condylar positioning in orthognathic surgery. (1988) (47)
Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies (2006) (46)
Exercise therapy for claudication. (1999) (45)
Association Between Physical Activity and Peripheral Artery Disease and Carotid Artery Stenosis in a Self-Referred Population of 3 Million Adults (2015) (45)
Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis (2020) (45)
Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. (2001) (45)
Pulmonary VO2 dynamics during treadmill and arm exercise in peripheral arterial disease. (2004) (44)
Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. (2007) (44)
Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease (2014) (43)
Trans-atlantic conference on clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) clinical trial methodology. (1999) (43)
Extended outcome assessment in the care of vascular diseases: revising the paradigm for the 21st century. Ad Hoc Committee to Study Outcomes Assessment, Society for Vascular Surgery/International Society for Cardiovascular Surgery, North American Chapter. (2000) (43)
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. (2018) (43)
Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy (2002) (42)
Clinical Trials in Peripheral Vascular Disease: Pipeline and Trial Designs An Evaluation of the ClinicalTrials.gov Database (2012) (42)
Anti-Chlamydial Antibiotic Therapy for Symptom Improvement in Peripheral Artery Disease: Prospective Evaluation of Rifalazil Effect on Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia pneumoniae Seropositive Patients (PROVIDENCE-1) (2009) (41)
Attenuation of exercise conditioning by low dose beta-adrenergic receptor blockade. (1983) (41)
Oral psoriasis. (1974) (40)
Lung volumes and apneic bradycardia in divers. (1970) (40)
Atherosclerotic Peripheral Vascular Disease Symposium II: executive summary. (2008) (39)
Multiple skeletal muscle mitochondrial DNA deletions in patients with unilateral peripheral arterial disease (2000) (39)
Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. (2020) (39)
Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease (2010) (39)
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. (2018) (38)
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients (2020) (38)
Community walking programs for treatment of peripheral artery disease. (2013) (38)
Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. (2015) (38)
Acute Limb Ischemia in Peripheral Artery Disease: Insights from EUCLID. (2019) (38)
Restoration of mandibular continuity defects using combinations of hydroxylapatite and autogenous bone: microscopic observations. (1990) (37)
Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: Safety, walking distance and endothelial function (2014) (37)
Effects of selective and nonselective beta-adrenergic blockade on mechanisms of exercise conditioning. (1986) (37)
Effect of Propionyl-L-carnitine on a Background of Monitored Exercise in Patients With Claudication Secondary to Peripheral Artery Disease (2011) (37)
Congenital teratoid cyst of the floor of the mouth. (1988) (37)
The US experience with cilostazol in treating intermittent claudication. (2005) (37)
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). (2017) (36)
A randomized trial of iloprost in patients with intermittent claudication (2008) (36)
Role of the 21,000 molecular weight polypeptide of Bacillus subtilis RNA polymerase in RNA synthesis. (1978) (36)
Russian Immigrant Cardiovascular Risk Assessment (2001) (35)
Risk assessment in the patient with established peripheral arterial disease (2007) (35)
Molecular characterization of tomato fruit polygalacturonase (1987) (35)
Current and Future Drug Therapies for Claudication (1997) (34)
Exercise Rehabilitation for Patients with Peripheral Arterial Disease (1995) (34)
Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial. (2018) (33)
Ankle-Brachial Index and cardiovascular events in atrial fibrillation (2016) (33)
Omega-3 fatty acids for intermittent claudication. (2013) (33)
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization (2020) (32)
Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. (2001) (31)
Tomato transgene structure and silencing (2005) (31)
Community-based walking exercise for peripheral artery disease: An exploratory pilot study (2015) (31)
Expression in Plants of a Bacterial Gene Coding for Glyphosate Resistance (1987) (30)
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation (2016) (30)
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study (2021) (29)
Peripheral arterial disease: medical care and prevention of complications. (2002) (29)
Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells. (2014) (29)
Metastatic carcinoma of the mandibular condyle: report of case. (1973) (28)
Aminoglycoside 3'‐phosphotransferase II (APH(3')II): Review of its safety and use in the production of genetically engineered plants (1994) (28)
Beta‐2 adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol (1985) (28)
A systematic review and meta-analysis of propionyl-l-carnitine effects on exercise performance in patients with claudication (2013) (28)
The Flavr Savr Tomato, an Early Example of RNAi Technology (2008) (27)
Stroke in Patients With Peripheral Artery Disease. (2019) (27)
S-adenosylmethionine levels and protein methylation during morphogenesis of Mucor racemosus (1980) (26)
Aspirin for prevention of cardiovascular events (2008) (26)
The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. (2006) (26)
Structure and expression of elongation factor 1 alpha in tomato. (1989) (26)
Negative impact of cardiac evaluation before vascular surgery (2000) (26)
TASC II section F on revascularization in PAD. (2007) (26)
Inflammatory Cytokines Associated With Failure of Lower-Extremity Endovascular Revascularization (LER): A Prospective Study of a Population With Diabetes (2019) (26)
Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials (2005) (25)
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial (2019) (25)
Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. (2015) (25)
Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. (2004) (25)
Nucleotide sequence of an EF-1α genomic clone from tomato (1990) (25)
Lack of relationship between gait parameters and physical function in peripheral arterial disease. (2006) (25)
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. (2018) (25)
The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. (2010) (24)
Antithrombotic Therapy for Peripheral Artery Disease in 2018. (2018) (24)
Bridging the quality gap in diabetic hyperlipidemia: a practice-based intervention. (2005) (24)
Short‐Term Effects of Estrogen and Progestin on Blood Pressure of Normotensive Postmenopausal Women (1991) (23)
Behavior-Change Intervention Targeting Physical Function, Walking, and Disability After Dysvascular Amputation: A Randomized Controlled Pilot Trial. (2018) (23)
Nutrition and the head and neck cancer patient. (1989) (23)
Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular risk (2006) (23)
Proarrhythmic Potential of Dronedarone: Emerging Evidence from Spontaneous Adverse Event Reporting (2012) (22)
Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia. (2012) (22)
Progression of asymptomatic peripheral artery disease over 1 year (2012) (22)
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial (2018) (22)
Regulatory assessment of the FLAVR SAVR tomato (1994) (21)
Clinical outcomes using aggressive approach to anatomic screening and endovascular revascularization in a veterans affairs population with critical limb ischemia (2009) (21)
What cost weight loss? (2012) (20)
Extubation criteria for oral and maxillofacial surgery patients. (1989) (20)
Differential synthesis of polypeptides during morphogenesis of Mucor (1980) (20)
The role of hemodynamics and duplex ultrasound in the diagnosis of peripheral arterial disease (1992) (20)
Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. (2017) (20)
A technique for simultaneous fracture repair and augmentation of the atrophic edentulous mandible. (1979) (20)
The balance between vascular alpha‐ and beta‐adrenoceptors is not changed in the elderly (1987) (20)
Progress towards the genetic engineering of tomato fruit softening (1989) (19)
Intracystic ameloblastoma in the young patient. Report of a case. (1967) (19)
Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study (2015) (19)
Antiplatelet therapy in peripheral artery disease. (2012) (19)
Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy (2004) (19)
Association of Perceived Stress Levels With Long-term Mortality in Patients With Peripheral Artery Disease (2020) (19)
Total Ischemic Event Reduction with Rivaroxaban after Peripheral Arterial Revascularization in the VOYAGER PAD Trial. (2021) (18)
Age does not alter human vascular and nonvascular β2‐adrenergic responses to isoproterenol (1988) (18)
Gingival and pharyngeal metastasis from a malignant melanoma. Report of a case. (1973) (18)
Optimal assessment of baseline treadmill walking performance in claudication clinical trials (2007) (18)
Peripheral arterial disease. (2019) (18)
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. (2011) (18)
Effects of non-insulin-dependent diabetes on oxygen consumption during treadmill exercise. (1995) (17)
Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. (2013) (17)
Hemangioma of the frontal bone: review of the literature and report of a case. (1991) (17)
Chinese translation and validation of the Walking Impairment Questionnaire in patients with peripheral artery disease (2011) (17)
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. (2012) (17)
The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease (2004) (17)
Prevalence of abnormal ankle-brachial index among individuals with low or intermediate Framingham Risk Scores. (2011) (16)
The Burden of Peripheral Artery Disease and the Role of Antiplatelet Therapy (2009) (16)
Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes. (2003) (16)
Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. (2020) (16)
Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration. (2008) (16)
Quality of life assessment in peripheral arterial disease. (1997) (16)
Use of preformed hydroxylapatite blocks for grafting in genioplasty procedures. (1986) (16)
l-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: A multicenter, randomized, double-blind, placebo-controlled trial (2012) (16)
Selective and nonselective β‐blockade of the peripheral circulation (1984) (16)
A technique of fixation of costochondral grafts for reconstruction of the temporomandibular joint. (1989) (16)
Measurement characteristics of the ankle–brachial index: results from the Action for Health in Diabetes study (2008) (16)
The Treatment Gap in Peripheral Artery Disease. (2017) (15)
Superiority ofTreadmill Walking Exercise Versus Strength Training forPatients With Peripheral Arterial Disease Implications fortheMechanism oftheTraining Response (1994) (15)
Determination of the Safety of Genetically Engineered Crops (1995) (15)
New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md. (2006) (15)
Nucleotide sequence of an EF-1 alpha genomic clone from tomato. (1990) (15)
Building a partnership between vascular medicine and vascular surgery: a coalition for the future of vascular care. (1996) (15)
Osteoid osteoma of the mandibular ramus. (1987) (14)
Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. (2013) (14)
Medical Treatment of Peripheral Arterial Disease (2008) (14)
Aspirin in primary prevention: can we individualize care? (2012) (14)
Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia. (2011) (14)
Contemporary Trends in Hospital Admissions and Outcomes in Patients With Critical Limb Ischemia: An Analysis From the National Inpatient Sample Database. (2021) (14)
Cardiovascular risk assessment in the development of new drugs for obesity. (2012) (14)
A validated biomarker panel to identify peripheral artery disease (2012) (14)
Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? (2012) (14)
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study (2018) (13)
Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. (2021) (13)
Plasma catecholamine responses to exercise after training with beta-adrenergic blockade. (1990) (13)
Assessing the clinical benefits of lipid-disorder drugs. (2014) (13)
Mechanical behavior of mandibular continuity defects reconstructed using combinations of hydroxylapatite and autogenous bone. (1990) (12)
Equal opportunities for all. (1991) (12)
Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery disease. (2013) (12)
Translation of RNAs Synthesized In Vivo and In Vitro from Bacteriophage SP82 DNA (1978) (12)
Hysterical trismus (conversion reaction). Report of a case. (1972) (12)
Treatment of disability in peripheral arterial disease: new drugs. (2004) (12)
Short communication & case reportAmeloblastic fibrosarcoma (1988) (12)
The In Vitro Transcriptional Specificity of RNA Polymerase Isolated from SP82-infected Bacillus subtilis (1976) (12)
Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease. (2017) (12)
New treatment options in intermittent claudication: the US experience. (2001) (12)
The nucleotide sequence of the 5' flanking region of a tomato polygalacturonase gene. (1988) (11)
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. (2021) (11)
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial (2021) (11)
Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication (2011) (10)
An alternative method of flap reflection for mandibular third molars. (1972) (10)
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. (2021) (10)
Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countries. (2016) (10)
Treatment of peripheral arterial disease. (2002) (10)
Age Does Not Alter Human Vascular and Nonvascular ??2-Adrenergic Responses to Isoproterenol (1989) (10)
Exercise physiology in cardiovascular diseases (1991) (10)
Masterclass series in peripheral arterial disease (2006) (10)
Basal-cell adenoma of the upper lip. Report of a case. (1973) (9)
The Application of Antisense RNA Technology to Plants (1989) (9)
Regulatory issues for commercialization of tomatoes with an antisense polygalacturonase gene (2007) (9)
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. (2021) (9)
Prognostic value of an increase in post-exercise ankle–brachial index (2017) (9)
An Aspirin a Day: Are We Barking Up the Wrong Willow Tree? (2010) (9)
Spontaneous dislocation of the mandible during prochlorperazine therapy: report of case. (1966) (8)
Omega-3 fatty acids for intermittent claudication. (2007) (8)
Effect of aerobic conditioning on the peripheral circulation during chronic beta-adrenergic blockade. (1984) (8)
Exercise in the treatment of intermittent claudication due to peripheral arterial disease (1991) (8)
Technique for rigid fixation of Le Fort and palatal fractures. (1986) (8)
TASC II Section F on Revascularization in PAD (2007) (8)
Medical management of peripheral arterial disease. (1994) (8)
Simultaneous inhibition of two tomato fruit cell wall hydrolases, pectinmethylesterase and polygalacturonase, with antisense gene constructs. (1993) (8)
A comparison of cilostazol and pentoxifylline for treating intermittent claudication (2001) (8)
Activity of Uridine Diphosphate N-Acetylglucosamine-4-Epimerase During Spherulation of Physarum polycephalum (1974) (8)
Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease (2021) (7)
Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity (2002) (7)
Actinomycosis of the anterior maxilla. (1977) (7)
The induction of new bone and cementum formation. V. A comparison of graft and control in sites in deep intrabony periodontal lesions. (1986) (7)
Contemporary Treatment of Venous Lower Limb Ulcers (1992) (7)
Consultations on patients with venous or arterial diseases. (2003) (7)
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial (2021) (7)
A critical review of antiplatelet treatment in peripheral arterial disease (2007) (7)
Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease: (2015) (7)
Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial (2019) (7)
Atherosclerotic Peripheral Vascular Disease Symposium II (2008) (7)
Preformed hydroxylapatite blocks for palatal grafting in orthognathic surgery. (1987) (7)
Computer-assisted mandibular condyle positioning in orthognatic surgery (1996) (7)
Improving the FDA's Advisory Committee Process (2012) (7)
Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID (2021) (6)
The efficacy of aspirin in peripheral arterial disease: an unresolved question. (2007) (6)
Cause of Death Among Patients With Peripheral Artery Disease (2020) (6)
Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease (2014) (6)
Section D -Chronic critical limb ischemia (2007) (6)
Peripheral Arterial Disease Handbook (2023) (6)
Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease (2020) (6)
Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial (2021) (6)
Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. (2019) (6)
Feasibility of Serial 6-min Walk Tests in Patients with Acute Heart Failure (2017) (6)
Can measuring the ankle-brachial index improve public health? (2008) (6)
Erratum: Cilostazol or pentoxifylline for claudication? (Circulation (1998) 98 Suppl I: (1-112)) (1999) (6)
Erratum: Evaluation and treatment of patients with lower extremity peripheral artery disease: Consensus definitions from Peripheral Academic Research Consortium (PARC) (Journal of the American College of Cardiology (2015) 65:(931-41)) (2015) (5)
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease (2020) (5)
Rivaroxaban in Peripheral Artery Disease after Revascularization. Reply. (2020) (5)
Chapter 17 – Pathophysiology of Peripheral Artery Disease, Intermittent Claudication, and Critical Limb Ischemia (2013) (5)
Proceedings from the Society of Interventional Radiology research consensus panel on critical limb ischemia. (2013) (5)
chapter 15 – Pathophysiology of Intermittent Claudication (2006) (5)
Blockade and intermittent claudication : placebo controlled trial of atenolol and nifedipine and their combination. Commentary (1992) (5)
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. (2019) (5)
Response to ‘Statement from the European Society of Vascular Surgery and the World Federation of Vascular Surgery Societies’ Inter-Society Consensus Document (TASC) III and International Standards for Vascular Care (ISVaC). (2014) (5)
Special populations in cardiovascular rehabilitation. Peripheral arterial disease, non-insulin-dependent diabetes mellitus, and heart failure. (1993) (5)
Peripheral Arterial Disease Is Not Associated with an Increased Prevalence of Intradialytic Cramps in Patients on Maintenance Hemodialysis (2002) (4)
The Society for Vascular Medicine: The first quarter century (2015) (4)
Omega-3 fatty acids for intermittent claudication. (2004) (4)
Expression of a Bacterial ACC Deaminase Gene in Tomato (1993) (4)
Intermittent claudication revisited: the value of medical therapy. (1999) (4)
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials (2022) (4)
Guideline‐directed statin intensification in patients with new or worsening symptoms of peripheral artery disease (2018) (4)
Submandibular swelling of unusual etiology. Report of a case. (1969) (4)
Aspirin for prevention of cardiovascular events : Is only effective in established cardiovascular disease (2008) (4)
MAJOR BLEEDING IN PATIENTS WITH PERIPHERAL ARTERY DISEASE: INSIGHTS FROM THE EUCLID TRIAL (2018) (4)
Abstract 12761: Incidence and Prevalence of Peripheral Artery Disease and Critical Limb Ischemia in an Insured National Population (2012) (4)
Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial (2020) (4)
Functional assessment of the claudicant importance of treatment and follow-up strategies. (1999) (4)
Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back. (2020) (3)
Multidisciplinary management: head and neck cancer. (1978) (3)
Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease (2020) (3)
Carnitine metabolism in peripheral arterial disease (1995) (3)
Peripheral arterial disease in the patient with diabetes mellitus. Can we make a difference? (1994) (3)
Pulmonary V̇O 2 dynamics during treadmill and arm exercise in peripheral arterial disease (2004) (3)
No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. (2020) (3)
Abstract 14299: Cardiovascular Events in Acute Coronary Syndrome Patients With Peripheral Arterial Disease Treated With Ticagrelor Compared to Clopidogrel: Data From the PLATO Trial (2011) (3)
Should an alternate ABI definition be adopted to evaluate risk? (2013) (3)
From the Masters: A sea-change for TransAtlantic Inter-Society Consensus (TASC) (2020) (3)
FIELD TRIALS AND RISK EVALUATION OF TOMATOES GENETICALLY ENGINEERED FOR ENHANCED FIRMNESS AND SHELF LIFE (1993) (3)
Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death. (2016) (3)
Methylation of elongation factor la from the fungus Mucor ( posttranslational modification / Nt-methyllysine / protein synthesis ) (2003) (3)
Exercise rehabilitation for treatment of claudication. (1996) (3)
238 A randomized, double-blind placebo-controlled study of NV1FGF gene therapy in critical limb ischemia patients (TAMARIS Study) (2011) (3)
Nonsurgical management of peripheral arterial disease. (1993) (2)
Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization (2021) (2)
Polyvascular Disease and Risk ofMajor Adverse Cardiovascular Events in Peripheral Artery Disease (2018) (2)
Exercise haemodynamic effects of beta-blockade and intrinsic sympathomimetic activity (2004) (2)
Abciximab added to urokinase increased amputation-free survival in peripheral arterial occlusion of the legs. (2002) (2)
Peripheral Arterial Disease in the Elderly (2005) (2)
Response to McDermott. (2014) (2)
Roxifiban in the prevention of ischemic events in peripheral arterial disease (2002) (2)
Etiology and Outcomes of Amputation in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. (2021) (2)
From the American Heart Association Measurement and Interpretation of the Ankle-Brachial Index : A Scientific Statement (2012) (2)
P935Effect of hypertension and systolic blood pressure on cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial (2019) (2)
Lost in translation: Why ‘lost to follow-up’ matters (2019) (2)
Clinical Diabetes/Therapeutics (2014) (2)
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF THE SAFETY AND EFFICACY OF PLASMID DNA EXPRESSING 2 ISOFORMS OF HEPATOCYTE GROWTH FACTOR IN PATIENTS WITH CRITICAL LIMB ISCHEMIA (2014) (2)
Identification of epsilon-N-mono-, epsilon-N-di-, and epsilon-N-trimethyllysine by high-performance liquid chromatography (1986) (2)
An improved splint in anterior osteotomies. (1974) (2)
Commentary re: Considerations about TASC II: Is it a Suitable Document for Specialists? (2007) (2)
New Drugs and Technologies What Cost Weight Loss? (2012) (1)
Disseminated sporotrichosis with mandibular involvement. (1981) (1)
AspirinforthePreventionofCardiovascularEvents in Patients With Peripheral Artery Disease A Meta-analysis of Randomized Trials (2009) (1)
Correction to: Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study (2018) (1)
Response by Hess and Hiatt to Letter Regarding Article, "A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative". (2017) (1)
Osteoradionecrosis is a common result of radiation therapy. (1981) (1)
Reviewers for the Journal, January-June 2016. (2016) (1)
Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD (2020) (1)
Heterogeneity of Risk and Benefit in Subgroups of COMPASS: Relatively Similar But Absolutely Different. (2019) (1)
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older (2021) (1)
P084 Chinese Translation and Validation of the Walking Impairment Questionnaire in Patients with Peripheral Arterial Disease (2011) (1)
Reply: ankle-brachial index in patients with nonvalvular atrial fibrillation. (2014) (1)
Chapter 22 – Peripheral Arterial Disease (2007) (1)
Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution (2018) (1)
Multiple oral petechiae and ecchymoses in a patient with osteoarthritis. (1987) (1)
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial (2022) (1)
Effects of avasimibe in claudicants with peripheral arterial disease (2003) (1)
An alternative method of flap reflection of mandibular third molars. (1972) (1)
COMMUNITY-BASED WALKING EXERCISE FOR PATIENTS WITH PERIPHERAL ARTERY DISEASE: A PILOT STUDY (2014) (1)
Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization. (2021) (1)
Chronic inflammation of residual submaxillary gland duct: report of case. (1967) (1)
The FDA Regulatory Process for Drug and Genetic Diagnostic Test Approvals (2008) (1)
Heart failure and peripheral artery disease: an unappreciated association. (2014) (1)
Selective and nonselective beta-blockade of the peripheral circulation. (1984) (1)
Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. (2021) (1)
Abstract 9800: Clinical Effects of the Phosphodiesterase Inhibitor K-134 in Peripheral Artery Disease and Claudication (2011) (1)
The Development of Therapeutics for Peripheral Artery Disease: A Unique Cardiovascular Risk Population. (2016) (1)
Contemporary Reviews in Cardiovascular Medicine Inflammation in Peripheral Artery Disease (2010) (1)
The use of integrated copies of plant viruses (1984) (1)
Automated Detection of Exercise Sessions in Patients With Peripheral Artery Disease: EVIDENCE FOR AN EXERCISE DOSE RESPONSE TO TRAINING. (2020) (1)
Vascular disease: Vorapaxar prevents progression of peripheral artery disease (2013) (1)
Treatment of ulcerative lesions of the oral cavity with gamma globulin. (1961) (1)
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial (2021) (1)
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. (2020) (1)
Differential Synthesis ofPolypeptides During Morphogenesis ofMucor (1980) (1)
Abstract 17116: Incidence and Costs of Major Atherothrombotic Vascular Events Among Patients With Peripheral Artery Disease After Revascularization (2020) (1)
AHA Scientific Statement A Call to Action: Women and Peripheral Artery Disease A Scientific Statement From the American Heart Association Endorsed by the Vascular Disease Foundation and its Peripheral Artery Disease Coalition (2012) (1)
Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD (2020) (1)
Abstract 16512: Amputation in Patients With Pad With and Without Diabetes: Insights From the EUCLID Trial (2020) (0)
Diagnosis of hypothyroidism after a surgical complication. (1975) (0)
Intensive blood pressure control reduces cardiac events in diabetic patients with arterial disease. (2002) (0)
Review: Magnetic resonance angiography detects lower-extremity arterial disease in claudication or critical limb ischemia (2001) (0)
Alan Hirsch, MD: 1954-2017. (2017) (0)
Structure and expression of elongation factor lco in tomato (0)
The Kids-DOTT Trial: Novel Aspects of the ‘Parallel Cohort RCT‘ Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism. (2009) (0)
Section G -Non-invasive vascular laboratory and imaging (2007) (0)
Abstract 16732: Urinary 11-Dehydro-Thromboxane B2 is Associated With Vascular and Non-Vascular Events in Atrial Fibrillation Patients (2014) (0)
Regarding: "Expression of myosin heavy chain isoforms in skeletal muscle of patients with peripheral arterial occlusive disease". (2000) (0)
Adenoid cystic carcinoma; a report of two cases. (1982) (0)
Review: β-blockers do not reduce walking capacity or calf blood flow in peripheral arterial disease (1992) (0)
Statins reduce major adverse limb events and mortality in patients with peripheral artery disease (2020) (0)
Immediate mandibular reconstruction following resection of ameloblastoma. (1982) (0)
Infectious contributions to atherosclerosis and vascular disease (2006) (0)
P5198The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID (2017) (0)
Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial (2014) (0)
Response by Jones et al to Letter Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease". (2017) (0)
and anaerobic threshold A sex-specific relationship between capillary density (2015) (0)
4065Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial (2018) (0)
Call to Action : Women and Peripheral Artery Disease : A Scientific Statement From the Print (2012) (0)
Abstract 16394: Aspirin for the Prevention of Cardiovascular Events in Patients without Clinical Cardiovascular Disease: a Meta-Analysis of Randomized Trials (2010) (0)
Section C -Intermittent claudication (2007) (0)
Abstract 3119: Long-term Safety of Cilostazol in Patients With Peripheral Artery Disease (2007) (0)
Section E -Acute limb ischemia (2007) (0)
AspirinforthePreventionofCardiovascularEvents in Patients With Peripheral Artery Disease (2017) (0)
COPD_A_292978 841..851 (2021) (0)
Calcium Channel Blockers May Increase Cardiovascular Risk in Diabetics (1998) (0)
Abstract 15943: Health Status and Quality of Life With Early Invasive and Non-invasive Treatment Strategies for Patients With Claudication (2020) (0)
OXYGEN UPTAKE KINETICS FOLLOWING LEG REPERFUSION IN PERIPHERAL ARTERIAL DISEASE (PAD) (2003) (0)
Response by Brass and Hiatt to Letter Regarding Article, "Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease". (2018) (0)
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial (2021) (0)
THE EFFECT OF INCREASE IN POST-EXERCISE ANKLE-BRACHIAL INDEX AMONG PATIENTS WITH NORMAL RESTING RESULTS (2016) (0)
DISABILITY AND QUALITY OF LIFE IN PEOPLE WITH PERIPHERAL ARTERIAL DISEASE AND INTERMITTENT CLAUDICATION. (2003) (0)
Compositions and methods for modulating endogenous cytokinin levels. (1990) (0)
Peripheral Arterial Disease Medical Therapy in Peripheral Artery Disease (2012) (0)
DIE APPLICATION OF ANTISENSE RNA TECHNOIDGY TO PlANTS (1989) (0)
type II diabetes mellitus Abnormal oxygen uptake kinetic responses in women with (2013) (0)
industry-sponsored clinical trials: the ARO-CRO model Improving academic leadership and oversight in large (2011) (0)
Effect of Work Rate on Muscle StO2 Kinetics in Peripheral Arterial Disease: 1531 (2006) (0)
Natural History and Outcomes of Patients with Critical Limb Ischemia in the Euclid Trial (2019) (0)
Section F -Revascularization (2007) (0)
TCT-555 The Association of Health-Related Quality-of-Life Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID Trial (2019) (0)
TCT-339 Types of Myocardial Infarction in Patients with Peripheral Artery Disease: Insights From EUCLID (2017) (0)
OXYGEN UPTAKE KINETICS DURING ARM AND LEG EXERCISE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE (PAD) (2002) (0)
TASCIII, do we need a new classification? (2014) (0)
Commentary. The fate of the claudicant--a prospective study of 1969 claudicants. (2011) (0)
Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fi brillation : a prospective multicentre cohort study (2015) (0)
CYP2C19 STATUS AND OUTCOMES IN THE EUCLID TRIAL (2018) (0)
Abstract 18984: Patterns and Predictors of Invasive Treatment Referral in Peripheral Artery Disease: Insights From the PORTRAIT Study (2016) (0)
Abstract 16190: Trends in Admissions and Outcomes in Patients With Chronic Limb-threatening Ischemia-a National Inpatient Sample Analysis (2020) (0)
The diagnosis, staging,and correction of facial deformities in the early and late teens. (1977) (0)
TICAGRELOR AND MAJOR ADVERSE LIMB EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS (2020) (0)
Abstract 3321: Gender Impacts Capillary Density and Skeletal Muscle Composition in Patients With Peripheral Arterial Disease (2007) (0)
Abstract 13462: 6-minute Walk Test Variability May be Reduced by a Structured Training and Monitoring Program, Potentially Facilitating Detection of Treatment Effects (2020) (0)
Obituary – John A Dormandy (5.3.1937–26.4.2019) (2019) (0)
Surgery for dental function: the team approach to Le Forte I osteotomy. (1984) (0)
A Collaborative Approach for Cardiovascular Health Promotion for Children and Youth : A Population and Public Health Perspective (2005) (0)
EFFICACY AND SAFETY OF RIVAROXABAN IN ELDERLY PATIENTS WITH SYMPTOMATIC PAD UNDERGOING REVASCULARIZATION: INSIGHTS FROM VOYAGER PAD (2021) (0)
Exercise Rehabilitation for Treatment of Claudication (1996) (0)
Professional interview: Current topics on TASC 2 (2007) (0)
Sounding the PAD alarm. GPs can diagnose peripheral artery disease with a simple ankle-and-arm blood pressure test. (2004) (0)
Abstract No. 43: Prevalence of abnormal ankle-brachial index among subjects with low-intermediate Framingham Risk Score (2010) (0)
AHA Scientific Statement Measurement and Interpretation of the Ankle-Brachial Index A Scientific Statement From the American Heart Association (2012) (0)
The Pathobiology of Acute Limb Ischemic Events and Stent Failure in Peripheral Artery Disease: A Step in the Right Direction. (2020) (0)
Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial ﬁ brillation: a prospective multicentre cohort study (2015) (0)
Plantar Flexion-Induced Entrapment of the Dorsalis Pedis Artery in a Teenaged Cross-Country Runner. (2020) (0)
EFFICACY AND SAFETY OF LOW-DOSE RIVAROXABAN IN SYMPTOMATIC PAD PATIENTS UNDERGOING REVASCULARIZATION CURRENTLY SMOKING: INSIGHTS FROM VOYAGER PAD (2021) (0)
University of Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation (2015) (0)
Ad Hoc Committee to Study Outcomes Assessment, Society for Vascular Surgery/International Society for Cardiovascular Surgery, North American (2000) (0)
Regulator antisense expression of a gene in plant cells. (1987) (0)
Clinical research studyInvited commentaryInvited Commentary (2006) (0)
Lessons Learned from a Phase I Clinical Trial of Mitochondrial Complex I Inhibition (2018) (0)
peripheral artery disease : A multicenter , randomized , double-blind , placebo-controlled trial l-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with (2012) (0)
Neither atenolol or nifedipine alone adversely affected walking distance but the combination decreased walking distance in intermittent claudication (1992) (0)
Evaluation and Treatment of Patients With Lower Extremity Peripheral ArteryDisease (2015) (0)
2259Ticagrelor in patients wtih symptomatic peripheral artery disease and prior coronary artery disease (2017) (0)
Abstract 24: Health Status Differences Between Early Invasive and Non Invasive Treatment Strategies in Patients With Peripheral Artery Disease: Insights From Portrait Registry (2020) (0)
Contemporary issues in peripheral vascular disease (1994) (0)
The composition and method of regulating the levels of endogenous cytokinins (1990) (0)
Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial (2019) (0)
Abstract 14141: A Contemporary Assessment of Lipid Lowering Therapies and Low-density Lipoprotein Cholesterol in Peripheral Artery Disease (2020) (0)
EXERCISE REHABILITATION FOR TREATMENT OF CLAUDICATION. AUTHORS' REPLY (1996) (0)
Effect of 13-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease (2005) (0)
eripheral Arterial Disease in Patients With Diabetes (2016) (0)
Abstract 13474: Rivaroxaban Reduces Major Cardiovascular and Limb Events in Patients With the High-risk Triad of Chronic Kidney Disease, Peripheral Artery Disease and Recent Lower Extremity Revascularization: Insights From VOYAGER PAD (2020) (0)
Methods and reagents to the ethylene level in plant modulating (1991) (0)
Histologic Evaluation of a Polylactic Acid Confluent Sheet in the Treatment of Osseous Defects (1992) (0)
submaximal exercise expression in human skeletal muscle following VEGF-A splice variants and related receptor (2015) (0)
POLYVASCULAR DISEASE WITH AND WITHOUT DIABETES AND THE RISK OF ADVERSE CARDIOVASCULAR AND LIMB EVENTS IN THE EUCLID TRIAL (2020) (0)
Exercise Rehabilitation for Intermittent Claudication (2003) (0)
New Insights on Plaque Erosion and Calci ﬁ ed Nodules (2014) (0)
Reply to Arno Vahl et al. "The VOYAGER PAD Trial in Surgical Perspective: A Debate". (2021) (0)
The effect of platelet protein and DNA on the measurement of human lymphocyte beta adrenergic receptor number. (1985) (0)
Propionyl-L-Carnitine (1998) (0)
Review: Gadolinium-enhanced magnetic resonance angiography is highly sensitive and specific for peripheral arterial disease (2001) (0)
Buccal airway device: an aid in the postoperative management of patients with wire fixation of the jaw. (1966) (0)
Ticagrelor versus Clopidogrel in Peripheral Artery Disease. (2017) (0)
Dosage and premedicating drugs. (1974) (0)
Peripheral Arterial Disease: State of the Art (2011) (0)
Reply: Endovascular-First Treatment of Peripheral Arterial Disease Remains Controversial. (2016) (0)
Apertognathia: its challenge and conquest. Report of a case. (1977) (0)
25. Carnitine metabolism in peripheral arterial disease (1995) (0)
The Society for Vascular Medicine and Biology (1999) (0)
Erratum: Cilostazol or pentoxifylline for claudication? (Circulation (October 27, 1998) 98:17 (I1-I1016)) (1999) (0)
Response to Letter Regarding Article, “Acute Pharmacological Conversion of Atrial Fibrillation to Sinus Rhythm” (2009) (0)
Abstract 20126: Factors Associated With Referral to Exercise Therapy in Patients With Peripheral Arterial Disease: Insights From the PORTRAIT Registry (2016) (0)
Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization (2021) (0)
Abstract 16501: VEGF and VEGF-R1 Levels in Skeletal Muscle of PAD Patients: A Report From the AMNESTI (Angiogenesis and Mechanisms of Exercise Training in PAD) Clinical Trial (2011) (0)
Plantar Flexion Induced Entrapment of The Dorsalis Pedis Artery In A Teenaged Cross-country Runner (2020) (0)
Nonatherosclerotic limb ischemia: Prompt evaluation and diagnosis (2016) (0)
From the American Heart Association A Call to Action: Women and Peripheral Artery Disease : A Scientific Statement (2012) (0)
TCT-92 Polyvascular Disease and Risk of Major Cardiovascular Events in Peripheral Artery Disease—Insights from EUCLID (2017) (0)
Section B -Management of cardiovascular risk factors and CO-existing disease (2007) (0)
Section A -Epidemiology of peripheral arterial disease (2007) (0)
Functional Benefits of Peripheral Vascular Bypass Surgery for Patients with Intermittent Claudication (1993) (0)
Medical Management of Peripheral Arterial Disease1 (1994) (0)
The effects of vascular disease and aging on the regulation of circulating endothelial progenitor cells. (2006) (0)
RISK AND COSTS AFTER PERIPHERAL REVASCULARIZATION IN PATIENTS WITH PERIPHERAL ARTERY DISEASE WITH AND WITHOUT DIABETES (2020) (0)
Peripheral Arterial Disease: Cost-Effective Diagnosis and Management (1999) (0)

This paper list is powered by the following services:

Other Resources About William R. Hiatt

en.wikipedia.org

What Schools Are Affiliated With William R. Hiatt?

William R. Hiatt is affiliated with the following schools:

William R. Hiatt's Academic­Influence.com Rankings